Nasrollahi-Shirazi Shahrooz, Unterwurzacher Markus, Berezhinskiy Hatice Oya, Alemanno Sophia, Hoetzenecker Konrad, Aigner Clemens, Jaksch Peter, Mohr Thomas, Kratochwill Klaus, Benazzo Alberto
Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.
Comprehensive Center for Chest Diseases (CCCD), Medical University of Vienna, Vienna, Austria.
Front Immunol. 2025 Aug 28;16:1616781. doi: 10.3389/fimmu.2025.1616781. eCollection 2025.
Induction therapy is widely used in lung transplantation to control the host alloresponse, reducing acute cellular rejection and improving graft survival. Despite its use, data on the biological effects of different induction agents remain limited.
This study examines serum proteomics profiles in lung transplant patients receiving alemtuzumab, anti-thymocyte globulin (ATG), or no induction therapy. Adult lung transplant recipients who underwent transplantation between 2007 and 2013 at the Medical University of Vienna were included. Using mass spectrometry (MS), serum samples were examined before transplantation (T1) and 12 months post-transplant (T2).
Among 102 patients (50 alemtuzumab, 34 ATG, 18 no induction), we identified significantly differentially expressed proteins over time and between groups at T2. In the alemtuzumab group, 40 proteins were differentially expressed (3 upregulated, 37 downregulated), in ATG, 22 proteins (3 upregulated, 19 downregulated), and none in the no-induction group. At T2, two proteins (fibulin-1 and fetuin-B) were downregulated between alemtuzumab and no induction, with no significant differences between alemtuzumab and ATG or ATG and no induction.
Our findings suggest alemtuzumab may have a stronger effect on circulating proteome. Further studies are warranted to elucidate the underlying mechanisms and explore potential clinical implications.
诱导疗法在肺移植中被广泛用于控制宿主同种异体反应，减少急性细胞排斥反应并提高移植物存活率。尽管使用了诱导疗法，但关于不同诱导剂生物学效应的数据仍然有限。
本研究检测了接受阿仑单抗、抗胸腺细胞球蛋白（ATG）或未接受诱导疗法的肺移植患者的血清蛋白质组学图谱。纳入了2007年至2013年在维也纳医科大学接受移植的成年肺移植受者。使用质谱法（MS）在移植前（T1）和移植后12个月（T2）检测血清样本。
在102例患者中（50例接受阿仑单抗，34例接受ATG，18例未接受诱导疗法），我们发现在T2时随时间推移以及组间存在显著差异表达的蛋白质。在阿仑单抗组中，有40种蛋白质差异表达（3种上调，37种下调），在ATG组中有22种蛋白质（3种上调，19种下调），而未接受诱导疗法的组中无差异表达。在T2时，阿仑单抗组与未接受诱导疗法组之间有两种蛋白质（纤连蛋白-1和胎球蛋白-B）下调，阿仑单抗组与ATG组之间或ATG组与未接受诱导疗法组之间无显著差异。
我们的研究结果表明阿仑单抗可能对循环蛋白质组有更强的作用。有必要进一步研究以阐明其潜在机制并探索潜在的临床意义。
